Photo by Chokniti Khongchum on Pexels

Japanese biotech startup Craif has secured $22 million in funding to advance its groundbreaking technology for early-stage cancer detection. Born out of Nagoya University in 2018, Craif’s innovative platform utilizes microRNA (miRNA) analysis to pinpoint cancer markers at their earliest stages. This technology holds the potential to dramatically improve patient outcomes and survival rates. The new funding will fuel accelerated research and development, enabling Craif to expand access to its life-saving technology. With global cancer diagnoses reaching nearly 20 million in 2022, the demand for accurate and early detection methods like Craif’s is greater than ever.